Recent years have witnessed significant progresses in the field of diabetes treatment, with a particular focus on GLP-1 receptor agonists. Among these novel therapies, retatrutide and trizepatide are emerging as https://idafhcj116004.thelateblog.com/39372299/novel-therapeutic-targets-in-diabetes-retatrutide-and-trizepatide